Liu Muxian, Wang Jie, Liu Meihong
Department of Gastroenterology, Dongguan Tungwah Hospital, Dongguan City 523000, Guangdong, China.
Department of Gastroenterology, Dongguan Tungwah Hospital, Dongguan City 523000, Guangdong, China.
Transl Oncol. 2025 Feb;52:102233. doi: 10.1016/j.tranon.2024.102233. Epub 2024 Dec 15.
The lysine oxidase (LOX) family, consisting of LOX and LOX-like-1-4 (LOXL1-LOXL4), catalyses the cross-linking reaction of collagen and elastin in the extracellular matrix (ECM). Numerous studies have demonstrated that LOX family members are dysregulated in a variety of cancers, including colorectal cancer (CRC), and play a key role in cancer cell migration, proliferation, invasion and metastasis. Targeting LOX family proteins with specific inhibitors has therefore been developed as a new therapeutic strategy for cancer. In this paper, we review the role of LOX enzymes in the development and progression of CRC. In addition, we address recent advances in the development of LOX/LOXL inhibitors, highlighting the potential use of this inhibitor as an effective and complementary treatment for CRC.
赖氨氧化酶（LOX）家族由LOX和类LOX-1-4（LOXL1-LOXL4）组成，催化细胞外基质（ECM）中胶原蛋白和弹性蛋白的交联反应。大量研究表明，LOX家族成员在包括结直肠癌（CRC）在内的多种癌症中表达失调，并在癌细胞迁移、增殖、侵袭和转移中起关键作用。因此，用特异性抑制剂靶向LOX家族蛋白已被开发为一种新的癌症治疗策略。在本文中，我们综述了LOX酶在CRC发生和发展中的作用。此外，我们还讨论了LOX/LOXL抑制剂开发的最新进展，强调了这种抑制剂作为CRC有效辅助治疗手段的潜在用途。
